Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
Dianthus Therapeutics (NASDAQ: DNTH), a clinical-stage biotech company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO Marino Garcia will lead a fireside chat on June 5, 2025, at 9:55 a.m. EDT in New York City. The presentation will be accessible via webcast in the Investors section of the company's website under "News and Events". Additionally, the company's management will be available for one-on-one meetings with investors during the conference.
Dianthus Therapeutics (NASDAQ: DNTH), un'azienda biotecnologica in fase clinica specializzata nello sviluppo di terapie complementari con anticorpi di nuova generazione per gravi malattie autoimmuni, ha annunciato la sua partecipazione al prossimo Jefferies Global Healthcare Conference. Il CEO Marino Garcia guiderà una conversazione informale il 5 giugno 2025 alle 9:55 EDT a New York. La presentazione sarà disponibile in diretta streaming nella sezione Investitori del sito web aziendale, sotto "News and Events". Inoltre, il management sarà disponibile per incontri individuali con gli investitori durante la conferenza.
Dianthus Therapeutics (NASDAQ: DNTH), una empresa biotecnológica en fase clínica enfocada en desarrollar terapias complementarias con anticuerpos de próxima generación para enfermedades autoinmunes graves, ha anunciado su participación en la próxima Jefferies Global Healthcare Conference. El CEO Marino Garcia dirigirá una charla informal el 5 de junio de 2025 a las 9:55 a.m. EDT en la ciudad de Nueva York. La presentación estará disponible vía webcast en la sección de Inversores del sitio web de la compañía, bajo "Noticias y Eventos". Además, la dirección de la empresa estará disponible para reuniones individuales con inversores durante la conferencia.
Dianthus Therapeutics (NASDAQ: DNTH)는 중증 자가면역 질환을 위한 차세대 항체 보체 치료제 개발에 주력하는 임상 단계의 바이오테크 기업으로, 다가오는 Jefferies Global Healthcare Conference에 참여한다고 발표했습니다. CEO 마리노 가르시아는 2025년 6월 5일 오전 9시 55분 EDT에 뉴욕에서 파이어사이드 채팅을 진행할 예정입니다. 발표는 회사 웹사이트의 투자자 섹션 내 '뉴스 및 이벤트'에서 웹캐스트로 시청할 수 있습니다. 또한, 회사 경영진은 컨퍼런스 기간 동안 투자자들과 1:1 미팅도 가질 예정입니다.
Dianthus Therapeutics (NASDAQ : DNTH), une société biotechnologique en phase clinique spécialisée dans le développement de thérapies complémentaires à base d'anticorps de nouvelle génération pour les maladies auto-immunes sévères, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. Le PDG Marino Garcia animera une discussion informelle le 5 juin 2025 à 9h55 EDT à New York. La présentation sera accessible en webcast dans la section Investisseurs du site internet de la société, sous "Actualités et Événements". De plus, la direction sera disponible pour des réunions individuelles avec les investisseurs durant la conférence.
Dianthus Therapeutics (NASDAQ: DNTH), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Antikörper-Komplement-Therapeutika der nächsten Generation für schwere Autoimmunerkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference angekündigt. CEO Marino Garcia wird am 5. Juni 2025 um 9:55 Uhr EDT in New York City ein Fireside-Chat leiten. Die Präsentation wird per Webcast im Investorenbereich der Unternehmenswebsite unter "News and Events" verfügbar sein. Außerdem steht das Management während der Konferenz für Einzelgespräche mit Investoren zur Verfügung.
- None.
- None.
NEW YORK and WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the Company’s participation in the Jefferies Global Healthcare Conference. Marino Garcia, Chief Executive Officer, will participate in a fireside chat on Thursday, June 5, 2025 at 9:55 a.m. EDT in New York City and will host one-on-one meetings with investors.
A live webcast of the Company’s presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit www.dianthustx.com and follow us on LinkedIn.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
FAQ
When is Dianthus Therapeutics (DNTH) presenting at the Jefferies Healthcare Conference 2025?
Who will represent Dianthus Therapeutics (DNTH) at the Jefferies Conference 2025?
How can investors access Dianthus Therapeutics' (DNTH) presentation at the Jefferies Conference?
What is Dianthus Therapeutics' (DNTH) main business focus?
